Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.

Sulaiman A, McGarry S, Li L, Jia D, Ooi S, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Gadde S, Li X, Wang L.

Mol Oncol. 2018 Apr;12(4):423-440. doi: 10.1002/1878-0261.12167. Epub 2018 Feb 21.

2.

Reframing Fantasy: Toward a Common Language of Hope, Dying, and Death in Long-Shot Pediatrics.

Addison C, Hempton C.

Am J Bioeth. 2018 Jan;18(1):36-38. doi: 10.1080/15265161.2017.1401169. No abstract available.

PMID:
29313781
3.

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.

Hilton JF, Clemons M, Pond G, Zhao H, Mazzarello S, Vandermeer L, Addison CL.

J Bone Oncol. 2017 Nov 8;10:6-13. doi: 10.1016/j.jbo.2017.11.001. eCollection 2018 Mar.

4.

MicroRNA-30b controls endothelial cell capillary morphogenesis through regulation of transforming growth factor beta 2.

Howe GA, Kazda K, Addison CL.

PLoS One. 2017 Oct 4;12(10):e0185619. doi: 10.1371/journal.pone.0185619. eCollection 2017.

5.

Factors Affecting Dietary Practices in a Mississippi African American Community.

White M, Addison C, Jenkins BWC, Henderson F, McGill D, Payton M, Antoine-LaVigne D.

Int J Environ Res Public Health. 2017 Jul 3;14(7). pii: E718. doi: 10.3390/ijerph14070718.

6.

"My Whole Life is Ethics!" Ordinary Ethics and Gene Therapy Clinical Trials.

Addison C, Lassen J.

Med Anthropol. 2017 Oct;36(7):672-684. doi: 10.1080/01459740.2017.1329832. Epub 2017 May 11.

PMID:
28494167
7.

Perception of Policy and Environmental Action to Promote Healthy Behaviors in African American Communities.

Addison C, Jenkins BW, White M, Henderson F, McGill DJ, Antoine-LaVigne D, Payton M.

Int J Environ Res Public Health. 2017 Mar 7;14(3). pii: E271. doi: 10.3390/ijerph14030271.

8.

Optimistic Bias, Risk Factors, and Development of High Blood Pressure and Obesity among African American Adolescents in Mississippi (USA).

White MS, Addison CC, Jenkins BW, Bland V, Clark A, LaVigne DA.

Int J Environ Res Public Health. 2017 Feb 20;14(2). pii: E209. doi: 10.3390/ijerph14020209.

9.

A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.

Laurie SA, Hao D, Leighl NB, Goffin J, Khomani A, Gupta A, Addison CL, Bane A, Seely J, Filion ML, Pond GR, Levine MN.

Lung Cancer. 2017 Feb;104:65-69. doi: 10.1016/j.lungcan.2016.12.004. Epub 2016 Dec 15.

PMID:
28213002
10.

Strategies for obtaining bone biopsy specimens from breast cancer patients - Past experience and future directions.

Ibrahim MF, Hilton J, Addison C, Robertson S, Werier J, Mazzarello S, Vandermeer L, Jacobs C, Clemons M.

J Bone Oncol. 2016 Jul 7;5(4):180-184. doi: 10.1016/j.jbo.2016.07.001. eCollection 2016 Nov.

11.

A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer.

Addison CL, Simos D, Wang Z, Pond G, Smith S, Robertson S, Mazzarello S, Singh G, Vandermeer L, Fernandes R, Iyengar A, Verma S, Clemons M.

J Bone Oncol. 2016 Jul 1;5(4):173-179. doi: 10.1016/j.jbo.2016.06.003. eCollection 2016 Nov.

12.

Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ERĪ± coinhibition.

Sulaiman A, Sulaiman B, Khouri L, McGarry S, Nessim C, Arnaout A, Li X, Addison C, Dimitroulakos J, Wang L.

FEBS Lett. 2016 Dec;590(24):4606-4616. doi: 10.1002/1873-3468.12496. Epub 2016 Dec 9.

13.

Staphylococcus aureus SaeR/S-regulated factors reduce human neutrophil reactive oxygen species production.

Guerra FE, Addison CB, de Jong NW, Azzolino J, Pallister KB, van Strijp JA, Voyich JM.

J Leukoc Biol. 2016 Nov;100(5):1005-1010. Epub 2016 Jun 22.

14.

Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.

Yeung C, Hilton J, Clemons M, Mazzarello S, Hutton B, Haggar F, Addison CL, Kuchuk I, Zhu X, Gelmon K, Arnaout A.

Cancer Metastasis Rev. 2016 Sep;35(3):427-37. doi: 10.1007/s10555-016-9631-3. Review.

PMID:
27405651
15.

Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS).

Fernandes R, Siegel P, Komarova S, Hilton J, Addison C, Ibrahim MF, Werier J, Dennis K, Singh G, Amir E, Jarvis V, Emmenegger U, Mazzarello S, Clemons M.

J Bone Oncol. 2016 Feb 23;5(2):57-62. doi: 10.1016/j.jbo.2016.02.004. eCollection 2016 Jun. Review.

16.

The Natural History of Subclinical Hyperthyroidism in Graves' Disease: The Rule of Thirds.

Zhyzhneuskaya S, Addison C, Tsatlidis V, Weaver JU, Razvi S.

Thyroid. 2016 Jun;26(6):765-9. doi: 10.1089/thy.2015.0470. Epub 2016 May 10.

PMID:
27090092
17.

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.

Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.

PLoS One. 2016 Mar 10;11(3):e0150567. doi: 10.1371/journal.pone.0150567. eCollection 2016.

18.

Issues Affecting the Loco-regional and Systemic Management of Patients with Invasive Lobular Carcinoma of the Breast.

Jacobs C, Clemons M, Addison C, Robertson S, Arnaout A.

Breast J. 2016 Jan-Feb;22(1):45-53. doi: 10.1111/tbj.12520. Review.

PMID:
26782951
19.

Implementing a Graduate Certificate Program in Cardiovascular Epidemiology: The Jackson Heart Study.

Campbell Jenkins BW, Addison C, Wilson G, Young L, Fields R, Woodberry C, Payton M.

Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010026. doi: 10.3390/ijerph13010026.

20.

Building Collaborative Health Promotion Partnerships: The Jackson Heart Study.

Addison CC, Campbell Jenkins BW, Odom D, Fortenberry M, Wilson G, Young L, Antoine-LaVigne D.

Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010025. doi: 10.3390/ijerph13010025.

21.

Gene Editing and Germ-line Intervention: The Need for Novel Responses to Novel Technologies.

Addison C, Taylor-Alexander S.

Mol Ther. 2015 Nov;23(11):1678-1680. doi: 10.1038/mt.2015.185. No abstract available.

22.

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.

Addison CL, Pond GR, Cochrane B, Zhao H, Chia SK, Levine MN, Clemons M.

J Bone Oncol. 2015 Jun 12;4(2):47-53. doi: 10.1016/j.jbo.2015.04.001. eCollection 2015 Jun.

23.

Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo.

Jia D, Tan Y, Liu H, Ooi S, Li L, Wright K, Bennett S, Addison CL, Wang L.

Oncotarget. 2016 Jan 5;7(1):771-85. doi: 10.18632/oncotarget.5819.

24.

NICE referral guidelines for suspected cancer: colorectal cancer and faecal occult blood testing.

Benton S, Steele R, Logan R, Djedovic N, Smith S, Addison C.

Ann Clin Biochem. 2016 Jan;53(Pt 1):7-9. doi: 10.1177/0004563215612507. Epub 2015 Oct 5. No abstract available.

PMID:
26438519
25.

Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.

Addison CL, Ding K, Seymour L, Zhao H, Laurie SA, Shepherd FA, Goss GD, Bradbury PA.

Lung Cancer. 2015 Nov;90(2):288-95. doi: 10.1016/j.lungcan.2015.09.004. Epub 2015 Sep 16.

PMID:
26415995
26.

Gene editing: Advising advice.

Addison C, Taylor-Alexander S.

Science. 2015 Aug 28;349(6251):935. doi: 10.1126/science.349.6251.935-a. No abstract available.

PMID:
26315423
27.

Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy.

Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M, Gonzalez-Angulo AM, Joyce JA, De Palma M, Pollard JW, Lewis CE.

Cancer Res. 2015 Sep 1;75(17):3479-91. doi: 10.1158/0008-5472.CAN-14-3587. Epub 2015 Aug 12.

28.

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, Howe GA, Bourgeois-Daigneault MC, Conrad DP, Daneshmand M, Breitbach CJ, Kirn DH, Raptis L, Sad S, Atkins H, Huh MS, Diallo JS, Lichty BD, Ilkow CS, Le Boeuf F, Addison CL, McCart JA, Bell JC.

Cancer Cell. 2015 Aug 10;28(2):210-24. doi: 10.1016/j.ccell.2015.06.009. Epub 2015 Jul 23.

29.

Invasive Pleomorphic Lobular Carcinoma of the Breast: Pathologic, Clinical, and Therapeutic Considerations.

Al-Baimani K, Bazzarelli A, Clemons M, Robertson SJ, Addison C, Arnaout A.

Clin Breast Cancer. 2015 Dec;15(6):421-5. doi: 10.1016/j.clbc.2015.06.010. Epub 2015 Jun 22. Review.

PMID:
26209026
30.

Flavivirus Antagonism of Type I Interferon Signaling Reveals Prolidase as a Regulator of IFNAR1 Surface Expression.

Lubick KJ, Robertson SJ, McNally KL, Freedman BA, Rasmussen AL, Taylor RT, Walts AD, Tsuruda S, Sakai M, Ishizuka M, Boer EF, Foster EC, Chiramel AI, Addison CB, Green R, Kastner DL, Katze MG, Holland SM, Forlino A, Freeman AF, Boehm M, Yoshii K, Best SM.

Cell Host Microbe. 2015 Jul 8;18(1):61-74. doi: 10.1016/j.chom.2015.06.007.

31.

Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.

Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L, Addison CL, Shepherd FA, Goss GD, Dimitroulakos J, Bradbury PA.

Clin Lung Cancer. 2015 Nov;16(6):e189-201. doi: 10.1016/j.cllc.2015.05.002. Epub 2015 May 13.

PMID:
26081815
32.

Treatment choices for patients with invasive lobular breast cancer: a doctor survey.

Jacobs C, Ibrahim MF, Clemons M, Hutton B, Simos D, Caudrelier JM, Graham ID, Smith S, Addison C, Arnaout A.

J Eval Clin Pract. 2015 Aug;21(4):740-8. doi: 10.1111/jep.12379. Epub 2015 Jun 9.

PMID:
26059404
33.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, Zhang J, Le Boeuf F, Arulanandam R, Stubbert L, Sampath P, Thorne SH, Paramanthan P, Chatterjee A, Strieter RM, Burdick M, Addison CL, Stojdl DF, Atkins HL, Auer RC, Diallo JS, Lichty BD, Bell JC.

Nat Med. 2015 May;21(5):530-6. doi: 10.1038/nm.3848. Epub 2015 Apr 20.

PMID:
25894825
34.

Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer?

Levasseur N, Clemons M, Hilton J, Addison C, Robertson S, Ibrahim M, Arnaout A.

Minerva Chir. 2015 Jun;70(3):181-93. Epub 2015 Mar 4. Review.

PMID:
25737461
35.

Evaluating the feasibility of performing window of opportunity trials in breast cancer.

Arnaout A, Robertson S, Kuchuk I, Simos D, Pond GR, Addison CL, Namazi M, Clemons M.

Int J Surg Oncol. 2015;2015:785793. doi: 10.1155/2015/785793. Epub 2015 Jan 20.

36.

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.

Addison CL, Pond GR, Zhao H, Mazzarello S, Vandermeer L, Goldstein R, Amir E, Clemons M.

Springerplus. 2014 Oct 1;3:577. doi: 10.1186/2193-1801-3-577. eCollection 2014.

37.

Sleep duration and mortality risk.

Addison C, Jenkins B, White M, LaVigne DA.

Sleep. 2014 Aug 1;37(8):1279-80. doi: 10.5665/sleep.3910. No abstract available.

38.

The association between individual and combined components of metabolic syndrome and chronic kidney disease among African Americans: the Jackson Heart Study.

Mendy VL, Azevedo MJ, Sarpong DF, Rosas SE, Ekundayo OT, Sung JH, Bhuiyan AR, Jenkins BC, Addison C.

PLoS One. 2014 Jul 3;9(7):e101610. doi: 10.1371/journal.pone.0101610. eCollection 2014.

39.

Essential role for the SLK protein kinase in embryogenesis and placental tissue development.

Al-Zahrani KN, Sekhon P, Tessier DR, Yockell-Lelievre J, Pryce BR, Baron KD, Howe GA, Sriram RK, Daniel K, Mckay M, Lo V, Quizi J, Addison CL, Gruslin A, Sabourin LA.

Dev Dyn. 2014 May;243(5):640-51.

PMID:
24868594
40.

Pharmacotherapy of bone metastases in breast cancer patients--an update.

Jacobs C, Simos D, Addison C, Ibrahim M, Clemons M.

Expert Opin Pharmacother. 2014 Jun;15(8):1109-18. doi: 10.1517/14656566.2014.903925. Epub 2014 Mar 28. Review.

PMID:
24673572
41.

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M.

Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.

42.

Bone-targeted therapy for metastatic breast cancer-Where do we go from here? A commentary from the BONUS 8 meeting.

Zhu X, Amir E, Singh G, Clemons M, Addison C.

J Bone Oncol. 2014 Feb 4;3(1):1-4. doi: 10.1016/j.jbo.2014.01.001. eCollection 2014 Mar.

43.

Joint effects of smoking and sedentary lifestyle on lung function in African Americans: the Jackson Heart Study cohort.

Campbell Jenkins BW, Sarpong DF, Addison C, White MS, Hickson DA, White W, Burchfiel C.

Int J Environ Res Public Health. 2014 Jan 28;11(2):1500-19. doi: 10.3390/ijerph110201500.

44.

Does estrogen play a role in response to adjuvant bone-targeted therapies?

Russell K, Amir E, Paterson A, Josse R, Addison C, Kuchuk I, Clemons M.

J Bone Oncol. 2013 Jul 5;2(4):167-73. doi: 10.1016/j.jbo.2013.06.001. eCollection 2013 Dec. Review.

45.

Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers.

Kuchuk I, Beaumont JL, Clemons M, Amir E, Addison CL, Cella D.

J Bone Oncol. 2013 Aug 8;2(4):154-7. doi: 10.1016/j.jbo.2013.07.004. eCollection 2013 Dec.

46.

Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre.

Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M.

J Bone Oncol. 2013 Oct 3;2(4):137-44. doi: 10.1016/j.jbo.2013.09.001. eCollection 2013 Dec.

47.

The use and effectiveness of complementary and alternative medicine for pain in sickle cell anemia.

Majumdar S, Thompson W, Ahmad N, Gordon C, Addison C.

Complement Ther Clin Pract. 2013 Nov;19(4):184-7. doi: 10.1016/j.ctcp.2013.05.003. Epub 2013 Jun 22.

PMID:
24199970
48.

The ZOOM trial: more boon than doom?

Hutton B, Addison CL, Clemons M.

Lancet Oncol. 2013 Sep;14(10):e387-8. doi: 10.1016/S1470-2045(13)70297-3. No abstract available.

PMID:
23993380
49.

A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.

Hutton B, Addison CL, Campbell K, Fergusson D, Mazarello S, Clemons M.

J Bone Oncol. 2013 May 15;2(3):123-31. doi: 10.1016/j.jbo.2013.05.001. eCollection 2013 Sep. Review.

50.

Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey.

Hutton B, Morretto P, Emmenegger U, Mazzarello S, Kuchuk I, Addison CL, Crawley F, Canil C, Malone S, Berry S, Fergusson D, Clemons M.

J Bone Oncol. 2013 Jun 21;2(3):105-9. doi: 10.1016/j.jbo.2013.05.002. eCollection 2013 Sep.

Supplemental Content

Loading ...
Support Center